These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30261472)

  • 1. Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population.
    Wargny M; Ducluzeau PH; Petit JM; Le May C; Smati S; Arnaud L; Pichelin M; Bouillet B; Lannes A; Blanchet O; Lefebvre P; Francque S; Van Gaal L; Staels B; Vergès B; Boursier J; Cariou B
    Atherosclerosis; 2018 Nov; 278():82-90. PubMed ID: 30261472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis.
    Emma MR; Giannitrapani L; Cabibi D; Porcasi R; Pantuso G; Augello G; Giglio RV; Re NL; Capitano AR; Montalto G; Soresi M; Cervello M
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Dec; 1865(12):158792. PubMed ID: 32777481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver fat accumulation is associated with circulating PCSK9.
    Ruscica M; Ferri N; Macchi C; Meroni M; Lanti C; Ricci C; Maggioni M; Fracanzani AL; Badiali S; Fargion S; Magni P; Valenti L; Dongiovanni P
    Ann Med; 2016 Aug; 48(5):384-91. PubMed ID: 27222915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis.
    Feder S; Wiest R; Weiss TS; Aslanidis C; Schacherer D; Krautbauer S; Liebisch G; Buechler C
    Lipids Health Dis; 2021 Jan; 20(1):6. PubMed ID: 33461570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis.
    Paquette M; Gauthier D; Chamberland A; Prat A; De Lucia Rolfe E; Rasmussen JJ; Kaduka L; Seidah NG; Bernard S; Christensen DL; Baass A
    Clin Biochem; 2020 Mar; 77():20-25. PubMed ID: 31972148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD.
    Grimaudo S; Bartesaghi S; Rametta R; Marra F; Margherita Mancina R; Pihlajamäki J; Kakol-Palm D; Andréasson AC; Dongiovanni P; Ludovica Fracanzani A; Lori G; Männistö V; Pellegrini G; Bohlooly-Y M; Pennisi G; Maria Pipitone R; Spagnuolo R; Craxì A; Lindén D; Valenti L; Romeo S; Petta S
    Liver Int; 2021 Feb; 41(2):321-332. PubMed ID: 33091218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A promising therapy for fatty liver disease: PCSK9 inhibitors.
    Han L; Wu L; Yin Q; Li L; Zheng X; Du S; Huang X; Bai L; Wang Y; Bian Y
    Phytomedicine; 2024 Jun; 128():155505. PubMed ID: 38547616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
    Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression.
    Gong Y; Ma Y; Ye Z; Fu Z; Yang P; Gao B; Guo W; Hu D; Ye J; Ma S; Zhang F; Zhou L; Xu X; Li Z; Yang T; Zhou H
    Metabolism; 2017 Nov; 76():32-41. PubMed ID: 28987238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
    Bril F; Barb D; Lomonaco R; Lai J; Cusi K
    J Hepatol; 2020 Mar; 72(3):401-410. PubMed ID: 31589891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary high oleic canola oil supplemented with docosahexaenoic acid attenuates plasma proprotein convertase subtilisin kexin type 9 (PCSK9) levels in participants with cardiovascular disease risk: A randomized control trial.
    Pu S; Rodríguez-Pérez C; Ramprasath VR; Segura-Carretero A; Jones PJ
    Vascul Pharmacol; 2016 Dec; 87():60-65. PubMed ID: 27374222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk.
    Arsenault BJ; Petrides F; Tabet F; Bao W; Hovingh GK; Boekholdt SM; Ramin-Mangata S; Meilhac O; DeMicco D; Rye KA; Waters DD; Kastelein JJP; Barter P; Lambert G
    J Clin Lipidol; 2018; 12(1):130-136. PubMed ID: 29103916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study.
    Peng J; Liu MM; Jin JL; Cao YX; Guo YL; Wu NQ; Zhu CG; Dong Q; Sun J; Xu RX; Li JJ
    Lipids Health Dis; 2022 Jan; 21(1):3. PubMed ID: 34996457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
    Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD
    Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition.
    Momtazi-Borojeni AA; Banach M; Ruscica M; Sahebkar A
    Expert Rev Clin Pharmacol; 2022 Oct; 15(10):1199-1208. PubMed ID: 36193738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between endotoxemia and histological features of nonalcoholic fatty liver disease.
    Kitabatake H; Tanaka N; Fujimori N; Komatsu M; Okubo A; Kakegawa K; Kimura T; Sugiura A; Yamazaki T; Shibata S; Ichikawa Y; Joshita S; Umemura T; Matsumoto A; Koinuma M; Sano K; Aoyama T; Tanaka E
    World J Gastroenterol; 2017 Jan; 23(4):712-722. PubMed ID: 28216979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.
    Puri P; Daita K; Joyce A; Mirshahi F; Santhekadur PK; Cazanave S; Luketic VA; Siddiqui MS; Boyett S; Min HK; Kumar DP; Kohli R; Zhou H; Hylemon PB; Contos MJ; Idowu M; Sanyal AJ
    Hepatology; 2018 Feb; 67(2):534-548. PubMed ID: 28696585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity.
    Barchetta I; Enhörning S; Cimini FA; Capoccia D; Chiappetta C; Di Cristofano C; Silecchia G; Leonetti F; Melander O; Cavallo MG
    BMC Med; 2019 Apr; 17(1):85. PubMed ID: 31035998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.